FDA Inspection 1077150 — Amerigen Pharmaceuticals Inc.
The FDA completed an inspection of Amerigen Pharmaceuticals Inc. on January 18, 2019 in Lyndhurst, NJ. The inspection was classified NAI (No Action Indicated — no objectionable conditions were found). Product area: Drugs.
Inspection Details
- Classification
- No Action Indicated (NAI) (NAI)
- End Date
- January 18, 2019
- Fiscal Year
- 2019
- Product Type
- Drugs
- Project Area
- Bioresearch Monitoring
- Location
- Lyndhurst, NJ (United States)
Additional Details
Postmarket Adverse Drug Experience (PADE)